Page 1,190«..1020..1,1891,1901,1911,192..1,2001,210..»

Fiction Book Releases To Check Out In 2020 – The Nerd Daily

Posted: January 11, 2020 at 5:50 am

Get ready to look forward to some great fiction book releases in 2020! Theres many exciting books heading your way and weve rounded up a few fiction books being released between January and June. Theres thrillers, historical fiction, books exploring family and friends, and much, much more! As for authors, theres those releasing their debut novel, along with familiar names such as Stephen King, Michele Campbell, Emily Giffin, and Josh Malerman all returning with new novels!

Already being hailed as aGrapes of Wrathfor our times and a new American classic, Jeanine CumminssAmerican Dirtis a rare exploration into the inner hearts of people willing to sacrifice everything for a glimmer of hope.

An electrifying story of two ambitious friends, the dark choices they make and the profound moment that changes the meaning of privacy forever.

TheNew York Timesbestselling authors ofThe Glass OceanandThe Forgotten Roomreturn with a glorious historical adventure that moves from the dark days of two World Wars to the turbulent years of the 1960s, in which three women with bruised hearts find refuge at Paris legendary Ritz hotel.

In this riveting and disquieting thriller about the secrets and betrayals that accompany exorbitant wealthimagineCrazy Rich Asiansas written by Gillian Flynntwo sisters from a Chinese-Indonesian family grapple with the past after one of them poisons their entire family.

From theNew York Timesbestselling author ofThe Other GirlandJustice for Saracomes a thrilling psychological drama about a woman who believes she escaped a brutal murder years agobut does anyone else believe her?

From the New York Times bestselling author of The House of the Spirits comes an epic novel spanning decades and crossing continents, following two young people as they flee the aftermath of the Spanish Civil War in search of a new place to call home.

A gripping thriller about a mans quest for the daughter no one else believes is still alive, from the acclaimed author ofThe Chalk ManandThe Hiding Place.

Alternating its present-day mystery with the story of the sisters childhood and adolescence, Long Bright River is at once heart-pounding and heart-wrenching: a gripping suspense novel that is also a moving story of sisters, addiction, and the formidable ties that persist between place, family, and fate.

From the award-winning author ofStation Eleven, an exhilarating novel set at the glittering intersection of two seemingly disparate events-a massive Ponzi scheme collapse and the mysterious disappearance of a woman from a ship at sea.

After a storm has killed off all the islands men, two women in a 1600s Norwegian coastal village struggle to survive against both natural forces and the men who have been sent to rid the community of alleged witchcraft.

One of the best writers in America (The Washington Post) delivers a mesmerising new novel in which Queen Elizabeths spymasters recruit an unlikely agent for an impossible mission: the only Muslim in England.

A powerful, emotional debut novel told in the unforgettable voice of a young Nigerian woman who is trapped in a life of servitude but determined to get an education so that she can escape and choose her own future.

Perfect for fans ofWhered You Go, BernadetteandSmall Admissions, a wry and cleverly observed debut novel about the privileged bubble that is Liston Heights Highthe micro-managing parents, the overworked teachers, and the students caught in the middleand the fallout for each of them when the bubble finally bursts.

A storm-struck island. A blood-soaked bed. A missing man. Senior Investigator Shana Merchant believes it all adds up to a killer in their midstand that murder is a family affair.

As much a story of resilience as it is suffering, The Love Story of the Century is a bittersweet account of the complexities of addiction, the power of creativity, and the redemption of love.

The story of a vibrant but dysfunctional family trapped together on a ten-day Mediterranean cruisea riveting, irresistible novel from bestselling author Amanda Eyre Ward

In the tradition of Daphne du Maurier, Shari Lapena, and Michelle Richmond comes a new thriller from the bestselling author of The Lake of Dead Languagesa twisty, harrowing storyset at a prestigious prep school in which one womans carefully hidden past might destroy her future.

When an exclusive New York womens workspace is rocked by the mysterious disappearance of its enigmatic founder, two sisters must uncover the haunting truth before they lose their friendships, their careersmaybe even their lives.

The #1 Bestselling authors of The Wife Between Us andAn Anonymous Girl deliver a thriller about a circle of friends with deadly intentionswhere trust is their weapon and revenge is their trigger.

From the #1New York Timesbestselling author ofMidwivesandThe Flight Attendantcomes a twisting story of love and deceit: an American man vanishes on a rural road in Vietnam, and his girlfriend, an emergency room doctor trained to ask questions, follows a path that leads her home to the very hospital where they met.

New friends can be found in unexpected places. For Bridget and Amy, that place was the cancer ward of an Anchorage hospital. Now, as each struggles to overcome loss, they lean on each other for supportsharing suppers, laughter and tears.

A mother and daughter with a shared talent for healingand for the conjuring of cursesare at the heart of this dazzling first novel.

Brilliantly combining fact and fiction, the historical and the horrific,The Deepreveals a chilling truth in an unputdownable narrative full of unnerving moments and with a growing, inexorable sense of foreboding.

A spellbinding story of a mother with nothing left to lose who sets out on an all-consuming quest for justice after her daughter is murdered on the town playground.

WithThe Year of the Locust, Hayes has penned a breathtaking story about cutting-edge science, a government conspiracy, and one mans desperate attempt to unravel it all. (Note: According to some retailers, this title has been pushed back yet again to June 2020. The UK version is currently set to September 2020, but after years of previous release dates and delays, this could still change).

A riveting debut novel set in contemporary Seoul, Korea, about four young women making their way in a world defined by impossibly high standards of beauty, secret room salons catering to wealthy men, strict social hierarchies, and K-pop fan mania.

Sheriff Sunshine Vicram finds her cup o joe more than half full when the small village of Del Sol, New Mexico, becomes the center of national attention for a kidnapper on the loose.

The New Husbandis a riveting thriller about the lies we tell ourselves from D. J. Palmer, the author ofSaving Meghan.

Fried Green Tomatoes and Steel Magnolias meet Dracula in this Southern-flavoured supernatural thriller set in the 90s about a womens book club that must protect its suburban community from a mysterious and handsome stranger who turns out to be a blood-sucking fiend.

From theNew York Times, USA Today, and internationally bestselling author of theAngelologyseries comes a bewitching gothic novel of suspense that plunges readers into a world of dark family secrets, the mysteries of human genetics, and the burden of family inheritance.

From theNew York Timesbestselling author ofA Simple Favorcomes an electrifying domestic thriller of how one womans life is turned upside down when her brother brings his new girlfriend to visitand no one is telling the truth about who they really are.

In June of 1940, when Paris fell to the Nazis, Hitler spent a total of three hours in the City of Lightabruptly leaving, never to return. To this day, no one knows why. The New York Timesbestselling author of the Aime Leduc investigations reimagines history in her masterful, pulse-pounding spy thriller,Three Hours in Paris.

In the thrilling sequel to Bird Box, the inspiration for the record-breaking Netflix film that starred Sandra Bullock and absolutely riveted Stephen King, New York Times bestselling author Josh Malerman brings unseen horrors to life.

Told over the course of a single day in 1927,The Paris Hourstakes four ordinary people whose stories, told together, are as extraordinary as the glorious city they inhabit.

From #1New York Timesbestselling author, legendary storyteller, and master of short fiction Stephen King comes an extraordinary collection of four new and compelling novellasMr. Harrigans Phone,The Life of Chuck,Rat, and the title storyIf It Bleedseach pulling you into intriguing and frightening places.

In All Adults Here, Emma Straubs unique alchemy of wisdom, humor, and insight come together in a deeply satisfying story about adult siblings, aging parents, high school boyfriends, middle school mean girls, the lifelong effects of birth order, and all the other things that follow us into adulthood, whether we like them to or not.

If you love Jennifer Robson orThe Crownyou will loveNew York Timesbestselling author Karen Harpers novel about Elizabeth, The Queen Mother.

Peter StraubsGhost Storymeets Liane MoriartysBig Little Liesin this American Indian horror story of revenge on the Blackfeet Indian Reservation.

Fans ofThe Chilbury Ladies ChoirandThe Guernsey Literary and Potato Peel Pie Societywill adoreThe Jane Austen Society A charming and memorable debut, which reminds us of the universal language of literature and the power of books to unite and heal. Pam Jenoff,New York Timesbestselling author ofThe Lost Girls of Paris

Her own past could be a reporters biggest story in this twisting thriller about murder and family secrets by theNew York Timesbestselling author T.R. Ragan.

From Michele Campbell, the bestselling author ofIts Always the Husbandcomes a new blockbuster thriller inThe Wife Who Knew Too Much.

In this wicked debut, safecracker Michael Maven must pull off the most dangerous theft of his long careeror his friends and family will be killed.

From theNew York Times bestselling author of the Hello Sunshine Book Club pickThe Other Woman, comes a compelling new domestic suspense novel about a family who is forever changed when a stranger arrives at their door.

In the irresistible new novel from the #1New York Timesbestselling author ofAll We Ever Wanted, a woman is falling hard for a man shes just met when he disappears without a trace on 9/11.

In 1935 three women are forever changed when one of the most powerful hurricanes in history barrels toward the Florida Keys inNew York Timesbestselling author Chanel Cleetons captivating new novel.

From theNew York Timesbestselling author ofThe Last House Guesta Reese Witherspoon Book Club pickcomes a riveting new novel of psychological suspense about a young woman plagued by night terrors after a childhood trauma who wakes one evening to find a corpse at her feet.

FromTheNew York Times-bestselling author ofThe Mothers, a stunning new novel about twin sisters, inseparable as children, who ultimately choose to live in two very different worlds, one black and one white.

The female cofounders of a wellness start-up struggle to find balance between being good people and doing good business, while trying to stay BFFs.

Like Loading...

More here:
Fiction Book Releases To Check Out In 2020 - The Nerd Daily

Posted in Human Genetics | Comments Off on Fiction Book Releases To Check Out In 2020 – The Nerd Daily

A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN – Dove Medical Press

Posted: January 10, 2020 at 10:42 am

Yaser H Gholami, 1 4 Lee Josephson, 3 Eman A Akam, 5 Peter Caravan, 5 Moses Q Wilks, 3 Xiang-Zuo Pan, 3, 6 Richard Maschmeyer, 1 Aleksandra Kolnick, 3, 7 Georges El Fakhri, 3 Marc D Normandin, 3 Zdenka Kuncic, 1, 4, 8Hushan Yuan 3

1The University of Sydney, Faculty of Science, School of Physics, Sydney, NSW, Australia; 2Bill Walsh Translational Cancer Research Laboratory, The Kolling Institute, Northern Sydney Local Health District, Sydney, Australia; 3Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; 4Sydney Vital Translational Cancer Research Centre, St Leonards, NSW, Australia; 5The Institute for Innovation in Imaging and the A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States; 6Bouve College of Health Sciences, CaNCURE Program, Northeastern University, Boston, MA, USA; 7Internal Medicine Residency Program, Lahey Hospital and Medical Center, Burlington, MA, USA; 8The University of Sydney Nano Institute, Sydney, NSW, Australia

Correspondence: Hushan YuanGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 149 13 th Street, Charlestown, MA 02129, USATel +1 617-643-1963Email hyuan@mgh.harvard.edu

Purpose: Using our chelate-free, heat-induced radiolabeling (HIR) method, we show that a wide range of metals, including those with radioactive isotopologues used for diagnostic imaging and radionuclide therapy, bind to the Feraheme (FH) nanoparticle (NP), a drug approved for the treatment of iron anemia.Material and methods: FH NPs were heated (120C) with nonradioactive metals, the resulting metal-FH NPs were characterized by inductively coupled plasma mass spectrometry (ICP-MS), dynamic light scattering (DLS), and r 1 and r 2 relaxivities obtained by nuclear magnetic relaxation spectrometry (NMRS). In addition, the HIR method was performed with [ 90Y]Y 3+, [ 177Lu]Lu 3+, and [ 64Cu]Cu 2+, the latter with an HIR technique optimized for this isotope. Optimization included modifying reaction time, temperature, and vortex technique. Radiochemical yield (RCY) and purity (RCP) were measured using size exclusion chromatography (SEC) and thin-layer chromatography (TLC).Results: With ICP-MS, metals incorporated into FH at high efficiency were bismuth, indium, yttrium, lutetium, samarium, terbium and europium (> 75% @ 120 oC). Incorporation occurred with a small (less than 20%) but statistically significant increases in size and the r 2 relaxivity. An improved HIR technique (faster heating rate and improved vortexing) was developed specifically for copper and used with the HIR technique and [ 64Cu]Cu 2+. Using SEC and TLC analyses with [ 90Y]Y 3+, [ 177Lu]Lu 3+ and [ 64Cu]Cu 2+, RCYs were greater than 85% and RCPs were greater than 95% in all cases.Conclusion: The chelate-free HIR technique for binding metals to FH NPs has been extended to a range of metals with radioisotopes used in therapeutic and diagnostic applications. Cations with f-orbital electrons, more empty d-orbitals, larger radii, and higher positive charges achieved higher values of RCY and RCP in the HIR reaction. The ability to use a simple heating step to bind a wide range of metals to the FH NP, a widely available approved drug, may allow this NP to become a platform for obtaining radiolabeled nanoparticles in many settings.

Keywords: nanomedicine, radiolabeling, radionuclide therapy, HIR, Feraheme

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Go here to read the rest:
A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press

Posted in Nano medicine | Comments Off on A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN – Dove Medical Press

Triple Negative Breast Cancer Treatment Market Combining Therapies – Communal News

Posted: January 10, 2020 at 10:42 am

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the global triple-negative breast cancer treatment market revenue to cross $720 Million by 2026 from an estimated valuation of just under $505 Million in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare.

The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

To Remain Ahead Of Your Competitors, Request a Sample Here

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market.

Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy.

Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Company Profiles

For Critical Insights on Market, Request For Methodology of Report @

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Related

Read more:
Triple Negative Breast Cancer Treatment Market Combining Therapies - Communal News

Posted in Nano medicine | Comments Off on Triple Negative Breast Cancer Treatment Market Combining Therapies – Communal News

Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 – WhaTech Technology and Markets News

Posted: January 10, 2020 at 10:42 am

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to crossUS$ 720 Mn by 2026from an estimated valuation of just underUS$ 505 Mn in 2018.

This is indicative of aCAGR of 4.7%during the period2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs.

Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare.

The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer.

This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market.

Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

For Critical Insights On The Triple Negative Breast Cancer Treatment Market, Request For Customization Here @www.persistencemarketresearch.com/requesttion/14305

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy.

Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Company Profiles

For In-Depth Competitive Analysis, AccessNow @www.persistencemarketresearch.com/checkout/14305

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Originally posted here:
Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 - WhaTech Technology and Markets News

Posted in Nano medicine | Comments Off on Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 – WhaTech Technology and Markets News

Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 – BioSpace

Posted: January 10, 2020 at 10:41 am

Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. We then produce the NextGen Bio Class of, twenty companies ranked based on several categories, including Finance, Collaborations, Pipeline, and Innovation. The companies were typically launched no more than 18 months before the list was created.

We thought it would be insightful to look back at our previous lists to see where some of those companies are today. Heres a look at the top three companies from the Top 20 Life Science Startups to Watch in 2018.

#1. BlueRock Therapeutics. Founded in 2016, BlueRock was #1 on our list of companies to watch in 2018. With facilities in Ontario, Canada; Cambridge, Massachusetts; and New York, New York, BlueRock launched in December 2016 with a $225 million Series A financing led by Bayer AG and Versant Ventures. The company focuses on cell therapies to regenerate heart muscle in patients who have had a heart attack or chronic heart failure, as well as therapies for patients with Parkinsons disease.

In October 2017, BlueRock and Seattle-based Universal Cells entered into a collaboration and license deal to create induced pluripotent stem (iPS) cell lines that can be used in the manufacture of allogeneic cellular therapies. Shortly afterwards, the company established its corporate headquarters in Cambridge, and in April 2018, established a research-and-development hub in New York City, as well as formalizing a sponsored research collaboration with the Center for Stem Cell Biology at Memorial Sloan Kettering (MSK) Cancer Center. The collaboration focuses on translating Ketterings expertise in creating multiple types of authentic neural cells from stem cells to address diseases of the central and peripheral nervous system. BlueRock also received $1 million from the State of New York and Empire State Development under its economic development initiatives program.

In April 2019, BlueRock partnered with Editas Medicine (which was on BioSpaces NextGen Bio Class of 2015 list) to combine their genome editing and cell therapy technologies to focus on novel engineered cell medicines. Part of the deal was to collaborate on creating novel, allogeneic pluripotent cell lines using a combination of Editas CRISPR genome editing technology and BlueRocks iPSC platform.

And finally, in August 2019, Bayer AG acquired BlueRock for the remaining stake in the company for about $240 million in cash and an additional $360 million in pre-defined development milestones.

#2. Prelude Fertility. Prelude Fertility is a bit of an outlier from the typical BioSpace NextGen company, because it isnt quite a biopharma company. It is a life sciences company whose business model is aimed at in vitro fertilization and egg freezing. It was founded with a $200 million investment by entrepreneur Martin Varsavsky. The investment was in the largest in vitro fertilization clinic in the Southeast, Reproductive Biology Associates of Atlanta, and its affiliate, My Egg Bank, the largest frozen donor egg bank in the U.S.

Since then it has expanded in various parts of the country, including adding San Francisco-based Pacific Fertility Center (PFC) to its network in September 25, 2017; partnering with Houston Fertility Institute and acquiring Vivere Health; partnering with the Advanced Fertility Center of Chicago; and in October 2018, partnered with NYU Langone Health.

In March 2019, Prelude merged with Inception Fertility to establish the Prelude Network as the fastest-growing network of fertility clinics and largest provider of comprehensive fertility services in the U.S. Inception is acting as the parent company, with the Prelude Network, both having board representatives from the previous organizations.

#3. Relay Therapeutics. Ranking #3 on our list for 2018, Relay Therapeutics launched in September 2016 with a $57 million Series A financing led by Third Rock Ventures with participation form D.E. Shaw Research. On December 14, 2017, it closed on a Series B round worth $63 million, led by BVF Partners, with new investors GV (formerly Google Ventures), Casdin Capital, EcoR1 Capital and Section 32.

The company focuses on the relationship between protein motion and function. It merges computational power with structural biology, biophysics, chemistry and biology. In December 2018, the company completed a $400 million Series C financing. It was led by the SoftBank Vision fund and included additional new investors, Foresite Capital, Perceptive Advisors and Tavistock Group. Existing investors also participated.

The company announced at the time it planned to use the funds to accelerate the implementation of its long-term strategy, expanding its discovery efforts, advancing existing programs into the clinic and improving its platform.

Read the rest here:
Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 - BioSpace

Posted in Massachusetts Stem Cells | Comments Off on Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 – BioSpace

Spinal Stenosis and Stem Cell Therapy … – Indiana Polyclinic

Posted: January 9, 2020 at 9:54 am

Spinal Stenosis and Stem Cell Therapy. Emerging Treatments for Spine Health

Our spines are responsible for our ability to stand upright, but they do so much more. Without a healthy spine, moving and even just standing can be painful or difficult. Injuries to the spine, even seemingly-minor ones, can have long-lasting, major impacts on our quality of life. Those injuries may not come from an outside source in some cases.

Spinal stenosis is a leading cause of back pain, weakness, and even numbness in parts of the body. While some people are born with the condition, it is generally something that develops over time, and is closely related to the aging process, as well as normal wear and tear on the bodys musculoskeletal system.

According to the National Institutes of Health, spinal stenosis is

Healthline further expands on this by stating,

Spinal stenosis does not have a single underlying cause that applies to all patients. While the most common cause of the disease is a significant change to the spine due to age-related wear and tear, there are other potential causes. For instance, spinal arthritis may be the culprit. In some individuals, inherited spine shapes can lead to the condition. Tumors in the spine, injuries due to external forces, Pagets disease, calcium deposits on spinal ligaments, and even too much fluoride can all lead to this disease.

Many patients experience no symptoms at all during the early stages of spinal stenosis. It is only once the condition develops more fully that they become noticeable. Ultimately, they can become so painful that they force people to change their lifestyles to accommodate a reduced range of motion, weakness, instability, or other effects.

Some of the more common symptoms of spinal stenosis include pain the neck, pain in the back, numbness or weakness in the arms or legs, pain radiating down one leg, pain and other problems with the feet, loss of feeling in one or both legs, and even difficultly having sex. Some patients with severe spinal stenosis may also experience loss of bladder or bowel control.

As with many other diseases, there are several different treatment options open to those suffering from spinal stenosis. The ultimate course of action will depend on several factors, including the severity of the symptoms.

Medications: Many different medications can help to alleviate the pain and discomfort associated with spinal stenosis. Over the counter pain relievers can help with early stages and mild symptoms. Older antidepressants have been shown to help reduce pain when taken before bed, and even anti-seizure medication can be used. In a worst-case scenario, opioids may be used, but this treatment is very much out of favor nowadays and should be discouraged.

Physical Therapy: May patients find that they alter their lifestyle due to pain from spinal stenosis. This can cause further loss of muscle tissue and strength. Physical therapy can be used to build strength and endurance, to improve balance, and even to help improve the stability of the spine.

Steroids: Depending on the area of the spine affected, steroid injections may be a potential treatment option. Steroids are generally only used when root irritation and inflammation are the underlying cause of the stenosis.

Decompression: Decompression is the process of using a needle-like tool to excise a portion of a thickened spinal ligament to alleviate pressure on the spine and spinal roots. It may also be called image-guided lumbar decompression or minimally invasive lumbar decompression.

Spinal Surgery: Surgery is used as a last resort, and may include any of a range of types, including:

Stem cells have been used successfully to treat an incredibly wide range of medical conditions in medical studies and laboratory settings. These are the building blocks of the bodys regenerative system they can heal and regenerate damaged cells, and even scar tissue. Stem cells can even transform themselves into other cell types to repair damage when necessary.

As such, these cells may be the ideal treatment option for patients suffering from spinal stenosis. Because stenosis is often caused by inflammation due to damage or irritation, and the growth of scar tissue, these cells hold the potential to address the underlying issue in a way that conventional treatments cannot.

There are two types of stem cells used in medical research studies and laboratory testing today autologous stem cells and allogeneic stem cells but they are not the same. Most studies focus on the use of autologous stem cells. These are harvested from the patients own body, usually from fat tissue, and are then injected into the area where treatment is needed. However, there are significant problems with this method.

Autologous stem cells are as old as the patient, meaning that they have lost much of their energy, and their ability to regenerate and heal has been compromised by accumulated damage and cellular mutations. Because of those mutations, theres even the chance that the patients immune system will attack the cells.

Allogeneic stem cells, on the other hand, are harvested from banked umbilical cord blood and tissue. These are blank cells, meaning that they are essentially invisible to the immune system. Theyre also very energetic, and because of their youth, they have almost limitless regenerative capabilities.

In the end, stem cell therapy may be able to provide relief from the symptoms of spinal stenosis. In some cases, it may be able to halt the progression of the disease. However, no stem cell therapy is approved by the FDA, and all treatments are considered experimental.

Source:

View post:
Spinal Stenosis and Stem Cell Therapy ... - Indiana Polyclinic

Posted in Indiana Stem Cells | Comments Off on Spinal Stenosis and Stem Cell Therapy … – Indiana Polyclinic

Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing – BioSpace

Posted: January 9, 2020 at 9:54 am

ROCKVILLE, Md., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors,today announced the appointment of Christopher Ballas, Ph.D., as Senior Vice President of Manufacturing. Dr. Ballas previously served in senior manufacturing roles at Rocket Pharmaceuticals and WuXi AppTec, with a focus on gene and cell-based therapies.

Our need for quality vector and cell production is growing as we advance our liquid and solid tumor CAR-T programs into the clinic in the United States. We intend to assume full control of our key manufacturing processes, said Larry (Lei) Xiao, Ph.D., ICTs Founder and Chief Executive Officer. Chris is a valued addition to the ICT management team, as he will lead our manufacturing efforts and the expansion of our related infrastructure, Dr. Xiao added.

Dr. Ballas brings more than 20 years experience of working on cell and gene therapies. Most recently, he served as Vice President of Manufacturing for Rocket Pharmaceuticals, a leading publicly traded U.S. gene therapy company. Previously, he served as Senior Director of Process Development and Commercialization for WuXi AppTec, where he was responsible for manufacturing operations and program management for gene therapy clients. Dr. Ballas oversaw key programs including CAR-T, TIL, and classic CD34+ stem cell gene therapy.

Prior to WuXi AppTec, Dr. Ballas ran autologous cell therapy clinical trials for Cook Medical. Dr. Ballas also held several roles at the Indiana University School of Medicine, where he developed the initial, scalable, clinical production capabilities for lentiviral vectors at the IU Vector Production Facility. As a faculty member, Dr. Ballas developed his own research programs targeting stem cells for gene therapy, which resulted in the collaborative development of an ultra-high throughput microinjection device with colleagues at the University of California Riverside (US9885059). In the past, Dr. Ballas served as an expert consultant to numerous companies on gene therapy and the production and use of viral vectors for gene therapies with contributions to Chemistry, Manufacturing and Control (CMC), regulatory filings, and regulatory meetings.

Dr. Ballas has a Ph.D. in Cellular and Molecular Pathology from the Vanderbilt University School of Medicine and was a Childrens Brittle Bone Foundation fellow during his post-doctoral fellowship at Case Western Reserve University School of Medicine.

Dr. Ballas said, I have a passion for solving the practical challenges associated with producing and using viral vectors to deliver genes and create differentiated therapies. ICTs CAR-T platform is unique and compelling, and I look forward to leveraging my experience to optimize and expand our manufacturing capability to produce world-class products with the potential to transform cancer immunotherapy.

About Innovative Cellular TherapeuticsInnovative Cellular Therapeutics (ICT) is a clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of liquid and solid tumors. ICT has achieved promising preclinical and clinical results in late-stage leukemia and lymphoma with its next generation CAR-T constructs. ICTs lead candidate in the United States, ICTCAR014, is a next generation CD19-targeting ArmoredCARTM T cell therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application clearance and is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. In solid tumor, ICT has compelling human data from IRB-approved proof-of-concept trials in China demonstrating the viability of its proprietary CoupledCARTM technology platform. For more information, please visitwww.ictbio.com.

See original here:
Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing - BioSpace

Posted in Indiana Stem Cells | Comments Off on Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing – BioSpace

Robots help them ‘find their passion’ – News Dispatch

Posted: January 9, 2020 at 9:54 am

MICHIGAN CITY Safe Harbors RoboBlitz Michigan City Robotics Team gathered at the old Mullen School on Saturday in eager anticipation of learning what their mission would be in this years FIRST Robotics Competition.

Nearly 60 other teams met at exactly the same time Saturday in various locations across the state to watch the live announcement, broadcast by FIRST Indiana Robotics, formerly IndianaFIRST Inc.

The name of the 2020 game? Infinite Recharge FIRST Rise, powered by Star Wars: Force for Change.

The theme this year is Star Wars; and theres three different sets of challenges that we have to accomplish in order to get a ranking point, said Michigan City High School sophomore Taylor Denvit.

The first challenge, she said, will be for the robot to shoot foam balls called power cells into a bay or goal.

Second, the robot will have to be able to spin a turntable according to specific instructions.

The third or end-game challenge will be for the robot to operate a teeter-totter-like" balancing rack.

I know from last year that you learn a lot about teamwork and incorporating different skills in these challenges, Denvit said. We learn so much, from mechanical to coding. We use a thing called CAD very intricate. This year, Im just hoping to gain new knowledge and have fun while doing it.

Denvit and the rest of the RoboBlitz Team met in their lab at the A.K. Smith Area Career Center on Monday night to talk strategy, familiarize themselves with the Infinite Recharge game field, and check out the FIRST Indiana Robotics-issued kit of parts, which included motors, batteries, control system components, construction materials and various automation components.

With a limited set of instructions from FIRST Indiana Robotics, the students will work with their mentors over the next six weeks to design, build, program and test robots.

We start from the frame and put everything on there ourselves, said MCHS senior Robert Lemon. We build a lot of what we put on there as well, and its good problem-solving experience. This year, Im hoping to take what we learned from the mistakes we made last year and bring that knowledge to this competition so we can be more successful. But the number one objective is just to have fun.

At the district competition, scheduled for later this semester, each teams robot will be judged based on effectiveness. The collaboration and determination of the students, who will work in alliances made up of three teams apiece, also will be measured.

Renee Becker-Blau, president of FIRST Indiana Robotics, said in a statement Monday, As a leader of this organization, I believe that our future is built better together and our students will improve the world with the skills they learn in this program.

"Between our mentors who teach students through hands-on learning, the problem-solving students do, not only with a robot but also to solve community challenges, and finally the focus of core values during times of intense competition these students are developing all the skills they need to be leaders in our futures.

FIRST (For Inspiration and Recognition of Science and Technology) aims to tackle declining enrollment in science, technology, engineering and math programs by using a competition sports-style model in an effort to make STEM learning fun for students.

The organizations mission proved effective in the case of Luke Cloninger, a member of the RoboBlitz Team all four years he was a student at Marquette High School. After graduating in 2015, Cloninger went on to Rose-Hulman Institute of Technology, where he began as a mechanical engineering major and ultimately graduated with a degree in computer science.

I dont think I would have been interested in either major without the experience I got here, said Cloninger, who now works for ArcelorMittal in Burns Harbor. I did my first coding here. I helped build the robots. I participated all four years of high school, and that experience definitely motivated me and made me sure that that was what I wanted to do.

This year, Cloninger has returned to work with the RoboBlitz students as a mentor.

The world is changing as far as career prospects, he said. Theres a big shortage of skilled workers, especially at the mill. We dont have enough people to fill engineering positions.

"So, I really hope that people will find their passion here whether it be engineering, marketing, programming, operating a CNC machine or mill. Whatever it may be, this is a place where they can gain the skills that they need to pursue future careers.

More than 3,600 teams consisting of more than 91,000 students and 26,000 professional mentors in 27 countries around the world will participate in FIRST Robotics Competitions this year at the district, state and world levels.

The Michigan City team brought home the title of state champions during the 2018 season.

Read more here:
Robots help them 'find their passion' - News Dispatch

Posted in Indiana Stem Cells | Comments Off on Robots help them ‘find their passion’ – News Dispatch

Red Shamrock: Fight never over, even when kids beat cancer – Iowa City Press-Citizen

Posted: January 9, 2020 at 9:52 am

Dick Hakes, Taking Liberties Published 10:13 a.m. CT Jan. 2, 2020 | Updated 10:49 a.m. CT Jan. 3, 2020

Finn is shown with his father, John Hall, during the nearly 18-month period about ten years ago in which the boy battled cancer through chemotherapy, radiation and immunotherapy.(Photo: Special to the Press-Citizen)

John Hall of Iowa City recalls how it all started in early 2009.

Before his son Finns third birthday, the boy started spiking fevers. Then he complained of stiff legs. Then a black eye showed up that would not go away.

A CT scan eventually produced what John said was the worst call I ever received.

A tumor on Finns cheek was traced to another on his adrenal gland. It was stage four neuroblastoma. He had about a 35% to 40% chance to survive it.

What followed was almost 18 months of aggressive treatment at University of Iowa Hospitals and Clinics (UIHC) chemotherapy sessions, two surgeries, two stem cell transplants, radiation and finally immunotherapy, which had just been green-lighted for broader use nationwide.

Those months became a heartbreakingly painful, sleepless, worrisome and all-encompassing ordeal for the entire family especially for Finn.

A recent photo of Finn Hall shows a smiling, cancer-free kid wearing a T-shirt promoting the Red Shamrock Foundation started by his father, John Hall.(Photo: Special to the Press-Citizen)

It worked, however, and the cancer disappeared.

We threw the cancer playbook at him, John said. I give the immunotherapy regiment credit for saving his life. It took care of the remaining cancer cells in the end. He was the first patient to complete that regiment at the U.

But it wasnt long after Finn came home and the family worked to return to a normal life that a new troubling reality emerged that led John to form the Red Shamrock Foundation.

Our only focus was getting past the cancer, he said. But now, because he had received so many harsh treatments at such a young age, we realized Finn would need some type of specialized care for the rest of his life.

Finn is 13 now and leading a pretty normal life, but because chemotherapy killed the seeds of his adult teeth, he still has all of his baby teeth, which will have to be replaced when he becomes an adult. He also has some minor hearing loss, kidney damage and must take growth hormones.

But it could have been a lot worse, John said. After cancer, kids sometimes have serious cognitive issues or chronic heart disease or secondary cancers due to the chemo and radiation. Some lose a limb or an organ.

He says he was amazed to learn that 95% of young cancer survivors can expect some type of serious chronic health condition by the time they reach age 45.

It hit me that people need to know about this, he said. I wanted to raise awareness that youre not done just because you have left the hospital.

John formed his nonprofit in 2011 with the help of friends who could handle obtaining legal status and help design a professional logo and web pages. A shamrock logo with a red heart seemed appropriate, given the familys Irish heritage.

The Red Shamrock Foundation mission is simple: Raise public awareness of the unique needs of kids who survive cancer, plus support survivorship programs and post-cancer research in Iowa.

As detailed on its website at http://www.redshamrock.org, the group sponsors three large fundraising events each year: A trail race at Regina High School in the spring, a golf outing in Mount Vernon in June and a Red Tie Gala during Childhood Cancer Awareness Month in September. Other money comes from donations and an online store operated through One Mission Fund Raising of Mount Vernon.

John Hall of Iowa City founded the Red Shamrock Foundation to raise public awareness that children who survive cancer will often face other medical challenges related to their treatment for the rest of their lives.(Photo: Dick Hakes/Special to the Press-Citizen)

As its director, John meets monthly with his board and often promotes the cause by speaking to civic groups. He says securing about $25,000 from the local 100 Men Who Careorganization a few years ago helped raise our profile in the community. All involved with Red Shamrock are unpaid volunteers.

In the past few years, the nonprofit has donated $110,000 for research projects at the university and through Passport for Care to assemble data on the health and needs of post-cancer patients.

Red Shamrock also provides educational materials for parents and teachers on how to explain cancer to kids and what to expect when a cancer survivor returns to class.

Finn was out of preschool for a year and a half, going through all he went through, then suddenly found himself back at preschool surrounded by 30 active, screaming kids, John said. The teachers were good, but Id drop him off and hed just sit in the middle of the room and cry. It took maybe six months for him to get comfortable again.

Dick Hakes(Photo: Special to the Press-Citizen)

The next step for Red Shamrock, John says, is to try to find a national partner and increase its scope beyond Iowa. A dedicated Team Red Shamrock group that participates in running events in other locations may be the catalyst for this, he said.

He has high praise for UIHC and points out that it now operates a survivorship clinic directed by Dr. Bill Terry, a pediatric oncologist.

The bottom line is to raise awareness of what pediatric cancer patients must face after theyve already fought the battle of their lives,John said. People need to understand that their fight is never over.

John is an Elkader native, a University of Iowa graduate in anthropology and a 30-year resident of Iowa City who works for Coldwell Banker in real estate. His wife Monica is a nurse at UIHC. Finn has an older brother, Sully.

Read or Share this story: https://www.press-citizen.com/story/life/2020/01/02/iowa-city-father-forms-red-shamrock-foundation-after-sons-cancer-fight/2794635001/

Link:
Red Shamrock: Fight never over, even when kids beat cancer - Iowa City Press-Citizen

Posted in Iowa Stem Cells | Comments Off on Red Shamrock: Fight never over, even when kids beat cancer – Iowa City Press-Citizen

Grit is the glue in life’s marathon! | Health – Wahpeton Daily News

Posted: January 9, 2020 at 9:51 am

As I reflect on my childhood, knowing what I know regarding Adverse Childhood Experiences or ACEs, and my score of a three, along with a high school graduating ACT score of a 15, it would seem unusual that in my freshman year at Northern State University that I, a probationary student would end the year on the Deans Presidential Scholarship List with a 4.0 GPA.

Equally astounding, was my completion of a Master of Science in Pastoral Care and Counseling degree with a 3.9 GPA. My life goal was to become an educator to make learning enjoyable and to be kind to others in the process. A defining moment in my life was when the well-intentioned high school counselor took me aside, and gently said, You might be able to be a teachers assistant, although because of your test score, not the actual classroom teacher.

It was exactly what I needed to hear. It agitated me just enough to set my sight on my goal and nothing was going to stop me from achieving it. I graduated from the university with an elementary education degree and a special education degree (K-12).

I went on to enjoy 27 delightful years as a classroom teacher until I had the opportunity to join St. Francis Health. Now in my seventh year, this life-giving Mission and Ministry position continues to exemplify how my students and parents continue to be my best teachers.

University of Pennsylvania Psychologist, Angela Duckworth, would call this grit. She defines grit as the perseverance and passion for long term goals with no particular concern for rewards or recognition along the way. It combines resilience, ambition, and self-control in pursuit of goals that take months, years, or even decades. Her published research in the book, Grit-The Power of Passion and Perseverance, a New York Times bestseller documents how grit predicts long-term success in nearly every realm of life.

Dr. Duckworths studies began when she was teaching math to seventh graders. She realized IQ wasnt the only factor separating successful students from those who struggled. Goals through time were the highly predictive of success. In most research studies, grit and measures of talent and IQ are unrelated, suggesting that talent puts no limits on capacity for passion and perseverance.

Since we can only teach what we truly know, below is Dr. Duckworths Pulse Check to gauge your current level of grit, considering how true the following are for you:

1. I enjoy projects that take years to complete.

2. I am working towards a very long-term goal.

3. What I do each day is connected to my deepest personal values.

4. There is at least one subject or activity that I never get bored of thinking about.

5. Setbacks dont discourage me for long.

7. I finish whatever I begin.

8. I never stop working to improve.

Your disposition to pursue long-term goals with passion and perseverance like risk for heart disease, interest in art, and your intelligence is both heritable and malleable. Ninety-nine percent of your genes are the same as mine or your neighbors and literally everyone else you know. Only a tiny fraction of human genes differ. These genetic differences among people are correlated with differences in our physical and psychological characteristics.

Our genetic heritage does not have complete authority over our life destiny UNLESS we allow it. From Harvard University Center on the Developing Child epigenetics research, we know that genes make a difference AND so does experience so dont assume that nature and nurture are mutually exclusive. It also reminds us of how essential it is to look for ways to enrich the environments of the young people in our lives. Epigenetics refers to changes in which genes are expressed and how early experiences alter gene expression and shape development.

According to Dr. Ducksworths research, here are some ways to encourage grit in others:

1. Model it. If you love what you do, let others know. Wear your passion on your sleeve. When you fail, openly share your frustration yet go out of your way to point our what you learned from the experience. Emphasize playing the long game in life. Life is a marathon, rather than a sprint.

2. Celebrate it. When you see grit, draw attention to it. Your work on this project has demonstrated tremendous perseverance. I know it took a huge effort on your part. Praise passion such as: You are really in the flow with this project and Im so happy for you.

3. Enable it. The paradox of grit is that determination of individuals is made possible by warmth and support of friends, families whether biological or chosen, teachers, and mentors.

God honors a beautiful blend of gift and grit! He gives the gift and expects us to have the grit to practice and learn how to use it effectively. ~ Beth Moore

For more information on how to most effectively use behavioral science to transform peoples lives to bring out their highest good go to: bcfg.wharton.upenn.edu Creating Enduring Behavior Change or Dr. Duckworths: Characterlab.org for actionable advice for parents and teachers based on science.

Sandy Block-Hansen, MS. St. Francis Healthcare Campus Family Footprints Coordinator. A Catholic Health Initiative Mission and Ministry program created to support, inform, and offer resources to parents in the role of parenting. She can be reached at sandrablock-hansen@catholichealth.net or 218.643.0475

See the original post:
Grit is the glue in life's marathon! | Health - Wahpeton Daily News

Posted in Epigenetics | Comments Off on Grit is the glue in life’s marathon! | Health – Wahpeton Daily News

Page 1,190«..1020..1,1891,1901,1911,192..1,2001,210..»